Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Microsoft, NVIDIA, Medtronic, The Progressive and Vertex Pharma

Read MoreHide Full Article

For Immediate Release

Chicago, IL – December 7, 2021 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corporation (MSFT - Free Report) , NVIDIA Corporation (NVDA - Free Report) , Medtronic plc (MDT - Free Report) , The Progressive Corporation (PGR - Free Report) and Vertex Pharmaceuticals Inc. (VRTX - Free Report) .

Here are highlights from Monday’s Analyst Blog:

Top Stock Reports for Microsoft, NVIDIA and Medtronic

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft, NVIDIA and Medtronic. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Microsoft have outperformed the S&P 500 over the past year (+52% vs. +25%). The Zacks analyst believes that Microsoft has been benefiting significantly from strength in its Azure cloud platform amid accelerated global digital transformation.

Microsoft Teams’ user growth has also been gaining on the back of the continued remote working trend as well as the mainstream adoption of hybrid/flexible work model. Solid uptake of new Xbox consoles is aiding the gaming segment performance. MSFT is also witnessing growth in the user base of its different applications, including Microsoft 365 suite, Dynamics and Power Platform.

(You can read the full research report on Microsoft here >>>)

NVIDIA shares have gained +135.3% in the year to date period against the Zacks General Semiconductor industry’s gain of +68.7%. The Zacks analyst believes that NVIDIA has been benefiting from the coronavirus-induced work and learn-from-home wave, as well as the strong growth in GeForce desktop and notebook Graphic Processing Units.

A surge in Hyperscale demand remains a tailwind for the company’s Data Center business. Expansion of NVIDIA GeForce NOW is expected to drive user base. Solid uptake of artificial intelligence-based smart cockpit infotainment solutions is another positive. Collaboration with Mercedes-Benz is also expected to further strengthen NVIDIA’s presence in the autonomous vehicles space.

(You can read the full research report on NVIDIA here >>>)

Shares of Medtronic have lost -13% in the last six months against the Zacks Medical Products industry’s loss of -7.3%; however, things seem to be improving for the company. The Zacks analyst believes that all of MDT’s major business groups have been reporting consistent gains, which highlights sustainability across groups and regions.

Medtronic’s second-quarter fiscal 2022 earnings beat the Zacks Consensus Estimate and it registered organic growth in the Cardiovascular, Neuroscience and Diabetes segments. The quarter’s gross and operating margins showed improvements on a year-over-year basis. MDT, however, continues to reel under pressure from health system labor shortages as well as the ongoing pandemic.

(You can read the full research report on Medtronic here >>>)

Other noteworthy reports we are featuring today include The Progressive and Vertex Pharma.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                        


Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.